Genome-wide Association Study of Susceptibility to Infection in Cystic Fibrosis

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2024 Aug 8

PMID 39117430

Authors

Boxi Lin

Jiafen Gong

Katherine Keenan

Fan Lin

Yu-Chung Lin

Julie Mesinele

Claire Calmel

Badreddine Mohand Oumoussa

Pierre-Yves Boelle

Loic Guillot

Harriet Corvol

Valerie Waters

Lei Sun

Lisa J Strug

Affiliations

Soon will be listed here.

Abstract

Background: is a common pathogen that contributes to progressive lung disease in cystic fibrosis (CF). Genetic factors other than CF-causing (CF transmembrane conductance regulator) variations contribute ∼85% of the variation in chronic infection age in CF according to twin studies, but the susceptibility loci remain unknown. Our objective is to advance understanding of the genetic basis of host susceptibility to infection.

Materials And Methods: We conducted a genome-wide association study of chronic infection age in 1037 Canadians with CF. We subsequently assessed the genetic correlation between chronic infection age and lung function through polygenic risk score (PRS) analysis and inferred their causal relationship through bidirectional Mendelian randomisation analysis.

Results: Two novel genome-wide significant loci with lead single nucleotide polymorphisms (SNPs) rs62369766 (chr5p12; p=1.98×10) and rs927553 (chr13q12.12; p=1.91×10) were associated with chronic infection age. The rs62369766 locus was validated using an independent French cohort (n=501). Furthermore, the PRS constructed from CF lung function-associated SNPs was significantly associated with chronic infection age (p=0.002). Finally, our analysis presented evidence for a causal effect of lung function on chronic infection age (β=0.782 years, p=4.24×10). In the reverse direction, we observed a moderate effect (β=0.002, p=0.012).

Conclusions: We identified two novel loci that are associated with chronic infection age in individuals with CF. Additionally, we provided evidence of common genetic contributors and a potential causal relationship between infection susceptibility and lung function in CF. Therapeutics targeting these genetic factors may delay the onset of chronic infections, which account for significant remaining morbidity in CF.

References

Saiman L, Garber E . Infection control in cystic fibrosis: barriers to implementation and ideas for improvement. Curr Opin Pulm Med. 2009; 15(6):626-31. DOI: 10.1097/MCP.0b013e328330d974. View

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):91-100. DOI: 10.1002/ppul.10127. View

Blanchard A, Waters V . Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection. J Pediatric Infect Dis Soc. 2022; 11(Supplement_2):S3-S12. DOI: 10.1093/jpids/piac052. View

Saiman L, Siegel J . Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003; 31(3 Suppl):S1-62. View

Sly P, Brennan S, Gangell C, de Klerk N, Murray C, Mott L . Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009; 180(2):146-52. DOI: 10.1164/rccm.200901-0069OC. View

Hemani G, Zheng J, Elsworth B, Wade K, Haberland V, Baird D . The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7. PMC: 5976434. DOI: 10.7554/eLife.34408. View

Watanabe K, Stringer S, Frei O, Mirkov M, de Leeuw C, Polderman T . A global overview of pleiotropy and genetic architecture in complex traits. Nat Genet. 2019; 51(9):1339-1348. DOI: 10.1038/s41588-019-0481-0. View

Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, Morales G . Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 2007; 104(19):8101-6. PMC: 1876578. DOI: 10.1073/pnas.0609213104. View

Gogarten S, Sofer T, Chen H, Yu C, Brody J, Thornton T . Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics. 2019; 35(24):5346-5348. PMC: 7904076. DOI: 10.1093/bioinformatics/btz567. View

10.

Yang J, Zeng J, Goddard M, Wray N, Visscher P . Concepts, estimation and interpretation of SNP-based heritability. Nat Genet. 2017; 49(9):1304-1310. DOI: 10.1038/ng.3941. View

11.

Pittman J, Calloway E, Kiser M, Yeatts J, Davis S, Drumm M . Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol. 2011; 46(5):497-504. PMC: 4239995. DOI: 10.1002/ppul.21397. View

12.

McColley S, Schechter M, Morgan W, Pasta D, Craib M, Konstan M . Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol. 2017; 52(7):909-915. DOI: 10.1002/ppul.23715. View

13.

Prince L . FGF10 and Human Lung Disease Across the Life Spectrum. Front Genet. 2018; 9:517. PMC: 6220039. DOI: 10.3389/fgene.2018.00517. View

14.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

15.

Widdicombe J, Wine J . Airway Gland Structure and Function. Physiol Rev. 2015; 95(4):1241-319. DOI: 10.1152/physrev.00039.2014. View

16.

Green D, Collaco J, McDougal K, Naughton K, Blackman S, Cutting G . Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. J Pediatr. 2012; 161(2):290-5.e1. PMC: 3682831. DOI: 10.1016/j.jpeds.2012.01.042. View

17.

Shrine N, Guyatt A, Erzurumluoglu A, Jackson V, Hobbs B, Melbourne C . New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet. 2019; 51(3):481-493. PMC: 6397078. DOI: 10.1038/s41588-018-0321-7. View

18.

Emond M, Louie T, Emerson J, Zhao W, Mathias R, Knowles M . Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 2012; 44(8):886-9. PMC: 3702264. DOI: 10.1038/ng.2344. View

19.

Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey B, Morgan W . Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros. 2012; 11(5):446-53. PMC: 4786375. DOI: 10.1016/j.jcf.2012.04.003. View

20.

Zhou J, Garber E, Saiman L . Survey of infection control policies for patients with cystic fibrosis in the United States. Am J Infect Control. 2008; 36(3):220-2. DOI: 10.1016/j.ajic.2007.05.009. View